CytoDyn Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Equity Awards (Tables)

Equity Awards (Tables)

12 Months Ended

May 31, 2022

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Option and Warrant Activity


							Weighted
							average
				Weighted			remaining		Aggregate
		Number of		average			contractual		intrinsic
(in thousands, except per share data)		shares		exercise price			life in years		value
Options and warrants outstanding at May 31, 2020		130,561		$	0.65		5.79		$	896
Granted		7,036		$	3.82
Exercised		(75,735)		$	0.59
Forfeited, expired, and cancelled		(1,088)		$	1.66
Options and warrants outstanding at May 31, 2021		60,774		$	0.95		4.37		$	68,061
Granted		50,205		$	0.72
Exercised		(5,677)		$	0.71
Forfeited, expired, and cancelled		(14,597)		$	1.36
Options and warrants outstanding at May 31, 2022		90,705		$	0.77		4.06		$	352
Options and warrants outstanding and exercisable at May 31, 2022		82,918		$	0.69		3.61		$	352

Schedule of options and warrants exercises


		Years ended May 31,
(in thousands)		2022			2021			2020
Option and warrant exercises:
Number of options and warrants exercised			5,677			75,735			101,853
Cash received		$	6,816		$	38,327		$	44,024
Aggregate intrinsic value		$	5,815		$	298,891		$	112,145

Schedule of assumptions used in determination of fair value


		Years ended May 31,
		2022			2021			2020
Expected Volatility		94.3% - 122.0	%		80.3% - 127.8	%		0.0% - 92.8	%
Weighted-Average Volatility		104.89	%		84.86	%		52.29	%
Expected Dividends		-	%		-	%		-	%
Expected Term (In years)		1.5 - 6.0			2.5 - 6.0			0.9 - 10.0
Risk-Free Rate		1.67	%		0.45	%		1.46	%